Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Lotrafiban

    go.drugbank.com/drugs/DB20872
    Experimental

    Lotrafiban is a small molecule drug. The usage of the INN stem '-fiban' in the name indicates that Lotrafiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

    Categories: Platelet Glycoprotein GPIIb-IIIa Complex, antagonists & inhibitors
  2. Drug

    Pixavir marboxil

    go.drugbank.com/drugs/DB21589
    Experimental

    Pixavir marboxil is a small molecule drug. The usage of the INN stem '-xavir' in the name indicates that Pixavir marboxil is a influenza CAP-dependent endonuclease inhibitor.

  3. Drug

    Lobeglitazone

    go.drugbank.com/drugs/DB09198
    Investigational

    Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes. … Unlike [DB01132], which is a dual PPAR agonist at PPAR-alpha and PPAR-gamma, Lobeglitazone is a pure PPAR-alpha agonist.

  4. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. … [A246015] Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.

  5. Drug

    Betazole

    go.drugbank.com/drugs/DB00272
    Approved

    A histamine H2 agonist used clinically to test gastric secretory function.

  6. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. … Pinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function.

  7. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved … Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type

  8. Drug

    Ifosfamide

    go.drugbank.com/drugs/DB01181
    ApprovedInvestigational

    Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

  9. Drug

    Ebastine

    go.drugbank.com/drugs/DB11742
    ApprovedInvestigationalWithdrawn

    Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.

    Categories: Antihistamines for Systemic Use
  10. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. … Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches.